Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01497067 · ClinicalTrials.gov registry record · NA

Long Term Safety Protocol for the AcrySof CACHET Phakic Lens

A NA study, sponsored by Alcon Research.

Completed
Registry status
NA
Development phase
657
Enrollment target

NCT01497067 is a NA study that has completed, run by Alcon Research. The registered enrollment target is 657 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01497067, a NA study, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
NA
Development phase
657 participants
Enrollment target

Study Summary

The purpose of this long term safety study is to estimate the annualized endothelial cell loss (ECL) rate (for up to 10 years following date of implantation) of subjects previously implanted with the ACRYSOF CACHET Phakic Intraocular Lens (L-series) from precursor clinical studies C-02-23, C-02-40, C-03-21 and C-05-57.

Interventions

  • DEVICE ACRYSOF CACHET Phakic Lens (L-series)

Trial Details

FieldValue
Enrollment Target 657 participants
Start Date 2011-11-21
Est. Completion 2018-06-15
Phase NA

Sponsor

Alcon Research

275 total trials

What the Registry Record Tells You About NCT01497067

The ClinicalTrials.gov registry entry for NCT01497067 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 657 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ACRYSOF CACHET Phakic Lens (L-series) is the first listed.

NCT01497067 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01497067 about?

NCT01497067 is a clinical study titled "Long Term Safety Protocol for the AcrySof CACHET Phakic Lens". The purpose of this long term safety study is to estimate the annualized endothelial cell loss (ECL) rate (for up to 10 years following date of implantation) of subjects previously implanted with the ACRYSOF CACHET Phakic Intraocular Lens (L-series) from precursor clinical studies C-02-23, C-02-40, ...

What is the current status of trial NCT01497067?

This trial is currently completed. It is a NA study. The enrollment target is 657 participants. The study started on 2011-11-21. Estimated completion is 2018-06-15.

What interventions are being tested in trial NCT01497067?

The interventions under investigation include: ACRYSOF CACHET Phakic Lens (L-series) (DEVICE).

Who is sponsoring clinical trial NCT01497067?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.